Sheng‐Yu Ku

Harvard University — United States

Medicine · Health Sciences

25h-index4.3kcitations208works7.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(86), Prostate Cancer Treatment and Research(86), Epigenetics and DNA Methylation(40), Cancer, Lipids, and Metabolism(26), Renal and related cancers(24)

Publications208 total

Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer
Molecular Cancer Therapeutics·2025· 2 cited
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer
Nature Communications·2025· 4 citedOpen Access
MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy
JCI Insight·2025· 6 citedOpen Access
Abstract 56: Multi-omic profiling of PSMA heterogeneity in prostate cancer liver metastases identifies new metabolomic targets
Cancer Research·2025
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation
Cancer Cell·2025· 13 cited
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Nature Communications·2024· 48 citedOpen Access
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer
Journal of Clinical Investigation·2024· 32 citedOpen Access
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
2024· 2 citedOpen Access
Supplementary Figures S1-S7 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Data from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Data from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Supplementary Tables S1-S10 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Supplementary Figures S1-S7 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Supplementary Tables S1-S10 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2024Open Access
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
2024· 4 citedOpen Access
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
Cancer Discovery·2023· 54 citedOpen Access
Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
Oncogene·2023· 1 citedOpen Access
Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Science Translational Medicine·2023· 39 citedOpen Access
PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
Oncogene·2023· 20 citedOpen Access
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
JNCI Journal of the National Cancer Institute·2023· 9 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Himisha Beltran(31), Leigh Ellis(15), Роберто Пили(13), David W. Goodrich(9), Swathi Ramakrishnan(9), Martin Bakht(9), Kei Mizuno(9), Michael Sigouros(8), Varadha Balaji Venkadakrishnan(8), Myles Brown(7), Remi Adelaiye‐Ogala(7), Loredana Puca(7), Juan Miguel Mosquera(6), Olivier Elemento(6), Eric Ciamporcero(6), Sreenivasulu Chintala(6), Li Shen(6), Kiersten Marie Miles(6), Yasutaka Yamada(6), Henry W. Long(5)